Affiliations: [a]
Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, Las Vegas, NV, USA
| [b]
Translational Neurodegenerative Research Lab, Roseman University, Las Vegas, NV, USA
| [c]
Department of Pharmacology and Neuroscience, Texas Tech University Health Science Center, School of Medicine, Lubbock, TX, USA
| [d]
Department of Neurology, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA
Correspondence:
[*]
Correspondence to: Marwan N. Sabbagh, MD, c/o Neuroscience Publications, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ 85013, USA. Tel.: +1 602 406 3593; Fax: +1 602 406 4104; E-mail: neuropub@barrowneuro.org.
Abstract: Background:Although insulin dysregulation and resistance likely participate in Alzheimer’s disease (AD) etiologies, little is known about the correlation between type 2 diabetes mellitus (T2DM) and the progression of cognitive decline in patients with AD. Objective:To determine whether AD patients with T2DM experience more rapid cognitive decline than those without T2DM. Methods:All cognitive performance data and the presence or absence of T2DM comorbidity in patients with AD were derived from the US National Alzheimer’s Coordinating Center’s (NACC) Uniform Data Set (UDS). A search of the UDS identified 3,055 participants with AD who had more than one epoch completed. The data set culled clinically diagnosed AD dementia patients who were assessed for diabetes type identified during at least 1 visit. These patients were divided into 2 groups based on whether they had a diagnosis of T2DM. The data from these groups were then analyzed for differences in cognitive decline based on neuropsychological test battery scores and a Clinician Dementia Rating using a general linear model. Results:Comparisons of the mean scores for 16 selected tests from the neuropsychological test battery showed no significant differences in baseline scores and scores at subsequent visits between the T2DM and nondiabetic groups. Conclusions:The results revealed no differences in cognitive decline metrics over the course of 5 visits in either study group. These data indicate that the presence of T2DM does not increase the rate of cognitive decline in AD. This finding contradicts expected disease burden and will need to be explored further.
Keywords: Alzheimer’s disease, cognitive progression, National Alzheimer’s Coordinating Center, neuropsychological test battery, type 2 diabetes mellitus, Uniform Data Set
